You have until tomorrow.
Stansberry Research

Dear Reader,

Until tomorrow, we're sharing an urgent message about the Melt-Up.

Over the coming weeks and months, I expect one sector of the market could skyrocket… sending certain stocks up 100% or more.

Biotech.

The fact is, you could realistically double your money before this Melt-Up is over if you own the best small biotech companies.

That's why, until tomorrow, November 19th, I urge you to have a look at our research firm's #1 biotech opportunity right now. It details a company whose newest breakthrough could be approved beginning December 31st.

Approval could send the stock soaring 200%.

In short, this little-known company owns a cancer device we've waited 17 years for… and which could treat 50% of all cancer patients worldwide.

When approval comes through – the stock could double very quickly… as we've seen many times before in this business.

For example…

  • Kite Pharma (KITE) is up 300% this year… after the FDA approved its first-ever gene therapy drug, Kymriah.
  • Clovis (CLVS) is up 111% this year after getting approval for their ovarian cancer drug, Rubraca.

That's why beginning soon… our top biotech pick could soar by hundreds of percent on news of approval for its new cancer device.

But for the biggest gain, you must get in BEFORE approval comes through.

So if you're interested, I urge you to get in by tomorrow.

After tomorrow, November 19th, we're removing this message from circulation, and you'll be too late for it.

You can get this offer here, until tomorrow.

Regards,

Steve Sjuggerud
Senior Analyst
Stansberry Research

P.S. Again, this opportunity expires tomorrow. Until then – we'll also show you how to claim a free ebook on this topic.


All contents of this e-mail are copyright 2017 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.

DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.

You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to info@stansberrycustomerservice.com.

To unsubscribe from this mailing, click here: Unsubscribe